Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart

Background Analyses in hospitalized patients and small autopsy series suggest that severe SARS-CoV-2 infection may affect the heart. We investigated heart tissue by in situ hybridization, immunohistochemistry and RNA sequencing in consecutive autopsy cases to quantify virus load and characterize cardiac involvement in COVID-19. Methods Left ventricular tissue from 95 deceased with diagnosed SARS-CoV-2 infection undergoing autopsy was analyzed and clinical data were collected. RNA was isolated to examine virus load of SARS-CoV-2 and its replication in the heart. A virus load >1000 copies per {micro}g RNA was defined as relevant. Viral RNA and inflammatory cells were assessed using histology. RNA sequencing and gene ontology (GO) enrichment were performed in 10 cases with high cardiac virus load and 10 age-matched cases without cardiac infection. Results A relevant SARS-CoV-2 virus load was detected in 41 out of 95 deceased (43%). The median cardiac virus load was 7952 copies per {micro}g RNA (IQR 2507, 32 005). In situ hybridization revealed SARS-CoV-2 RNA primarily in the interstitium or interstitial cells. Virus detection was not associated with increased inflammatory cells. Relevant cardiac infection was associated with increased expression of the entry factor TMPRSS2. Cardiac virus replication was found in 14/95 hearts (15%). Remarkably, cardiac virus replication was associated with shorter time between diagnosis and death. RNA sequencing revealed clear activation of immune response pathways to virus infection and destruction of cardiomyocytes. Hearts with high virus load showed activation of the GO term ''extracellular exosomes''. Conclusion SARS-CoV-2 infection including virus replication and distinct transcriptomic alterations without signs of myocarditis demonstrate a cardiac involvement. In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.

[1]  Silva Kasela,et al.  Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells , 2020, Cell.

[2]  Paul J. Hoover,et al.  Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients , 2020, bioRxiv.

[3]  S. Goldhaber,et al.  Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[4]  Samin K. Sharma,et al.  Characterization of Myocardial Injury in Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[5]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[6]  F. Heppner,et al.  Why misinterpretation of electron micrographs in SARS-CoV-2-infected tissue goes viral , 2020, The Lancet.

[7]  B. Conklin,et al.  SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients , 2020, bioRxiv.

[8]  J. R. Rebello Pinho,et al.  SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome , 2020, The Lancet Child & Adolescent Health.

[9]  K. Knowlton Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus , 2020, Journal of Molecular and Cellular Cardiology.

[10]  Victor G. Puelles,et al.  SARS-CoV-2 renal tropism associates with acute kidney injury , 2020, The Lancet.

[11]  A. Kurniawan,et al.  Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[12]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[13]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[14]  J. Q. Brown,et al.  Unexpected Features of Cardiac Pathology in COVID-19 Infection. , 2020, Circulation.

[15]  J. Lacy,et al.  Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series , 2020, The Lancet.

[16]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[17]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[18]  K. Kotani,et al.  COVID‐19—Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[20]  C. Hamm,et al.  Detection of viral SARS‐CoV‐2 genomes and histopathological changes in endomyocardial biopsies , 2020, ESC heart failure.

[21]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[22]  A. Frangakis,et al.  SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes , 2020, bioRxiv.

[23]  J. Vincent,et al.  Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients , 2020, Critical Care.

[24]  R. Claus,et al.  Postmortem Examination of Patients With COVID-19. , 2020, JAMA.

[25]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[26]  Mahmud Arif Pavel,et al.  The role of high cholesterol in age-related COVID19 lethality. , 2020, bioRxiv.

[27]  K. Mertz,et al.  Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction , 2020, Histopathology.

[28]  Sara E. Miller,et al.  Electron microscopy of SARS-CoV-2: a challenging task , 2020, The Lancet.

[29]  M. Hoffmann,et al.  A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells , 2020, Molecular Cell.

[30]  E. Arbustini,et al.  Myocardial localization of coronavirus in COVID‐19 cardiogenic shock , 2020, European journal of heart failure.

[31]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[32]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[33]  Susanne Pfefferle,et al.  Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[34]  Zhifeng Liu,et al.  Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study , 2020, medRxiv.

[35]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[36]  Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute , 2020 .

[37]  C. Emiliani,et al.  The Role of Extracellular Vesicles in Viral Infection and Transmission , 2019, Vaccines.

[38]  D. Topham,et al.  Novel Functions of IFI44L as a Feedback Regulator of Host Antiviral Responses , 2019, Journal of Virology.

[39]  S. Willems,et al.  Cardiac glial cells release neurotrophic S100B upon catheter-based treatment of atrial fibrillation , 2019, Science Translational Medicine.

[40]  Yukiko Shimizu,et al.  TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection , 2019, Journal of Virology.

[41]  S. Blankenberg,et al.  Precursor proadrenomedullin influences cardiomyocyte survival and local inflammation related to myocardial infarction , 2018, Proceedings of the National Academy of Sciences.

[42]  S. Blankenberg,et al.  Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis , 2017, Journal of immunology research.

[43]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[44]  Fátima Sánchez-Cabo,et al.  GOplot: an R package for visually combining expression data with functional analysis , 2015, Bioinform..

[45]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[46]  S. Blankenberg,et al.  Cardiac Fibroblasts Aggravate Viral Myocarditis: Cell Specific Coxsackievirus B3 Replication , 2014, Mediators of inflammation.

[47]  Sören Müller,et al.  APADB: a database for alternative polyadenylation and microRNA regulation events , 2014, Database J. Biol. Databases Curation.

[48]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[49]  M. Bouvier,et al.  MHC class I antigen presentation: learning from viral evasion strategies , 2009, Nature Reviews Immunology.

[50]  E. Rassart,et al.  Neuroprotective Effect of Apolipoprotein D against Human Coronavirus OC43-Induced Encephalitis in Mice , 2008, The Journal of Neuroscience.

[51]  C. Peyrefitte,et al.  Evidence for in vitro falsely-primed cDNAs that prevent specific detection of virus negative strand RNAs in dengue-infected cells: improvement by tagged RT-PCR. , 2003, Journal of virological methods.

[52]  T. Fuerst,et al.  Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. , 1994, Virology.